{
    "nct_id": "NCT05721222",
    "official_title": "Phase 1/2 Study of PRO1160 in Patients With Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC), or Non-Hodgkin Lymphoma (NHL)",
    "inclusion_criteria": "* Pathologically confirmed metastatic or unresectable solid malignancy including Renal Cell carcinoma, Nasopharyngeal carcinoma or Stage III or IV Non Hodgkin Lymphoma\n* Relapsed or refractory disease following prior systemic therapies known to confer medical benefit\n* Willing to provide a tumor sample (archive tissue or fresh biopsy)\n* ECOG performance status 0 or 1\n* Measurable disease per RECIST v1.1 for RCC and NPC and per Lugano for NHL\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with anti-CD70 directed therapy\n* Other malignancy within 3 years\n* Active CNS metastases (treated, stable CNS metastases are allowed)\n* Uncontrolled Grade 3 or greater infection within 2 weeks\n* Positive for HBV, HCV or HIV\n* Use of a strong P450 CYP3A inhibitor within 14 days (dose escalation only)\n* Additional protocol defined inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": ""
}